LumiThera

Valeda is a medical device that delivers photobiomodulation using 590 nm, 660 nm, and 850 nm wavelengths of light to stimulate mitochondrial activity in retinal cells. It is the first FDA-authorized treatment for early and intermediate dry AMD that improves visual acuity without drugs, injections, or surgery.

Valeda's FDA authorization is based on the LIGHTSITE III trial, a 24-month, double-masked, sham-controlled study of 98 patients (145 eyes). The trial found that 84% of treated patients maintained or improved vision at about two years, with more than 60% gaining at least one line of visual acuity (per the LIGHTSITE III study results published in Retina, 2024).

Valeda is distributed globally by Alcon, the eye care division of Novartis. Alcon markets the device through its surgical and vision care channels to retina specialists and ophthalmology practices in the United States.

LumiThera is a medical device company, not a family office or asset manager. It develops, manufactures, and commercializes the Valeda photobiomodulation device. No investment or wealth management activity has been disclosed.

LumiThera lists its headquarters in Poulsbo, Washington, with an additional office in Tokyo, Japan. The company's operational status in Japan is not publicly detailed.